• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $SGMO

    Sangamo Therapeutics Inc.

    Subscribe to $SGMO
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; BIVV003, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease; ST-400, a cell therapy, which is in Phase I/II Thales clinical trials for the treatment of transfusion dependent beta thalassemia. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, an anti-CD19 CAR-T cell therapy for the treatment of cancer. ST-101 gene therapy for phenylketonuria. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.

    IPO Year: 2000

    Exchange: NASDAQ

    Website: sangamo.com

    Peers

    $MCRB

    Recent Analyst Ratings for Sangamo Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    12/13/2024$7.00Hold → Buy
    Truist
    12/10/2024$10.00Buy
    H.C. Wainwright
    11/3/2023$6.00 → $2.00Outperform → Sector Perform
    RBC Capital Mkts
    4/28/2023$5.00 → $1.50Neutral → Underperform
    BofA Securities
    2/27/2023$16.00Neutral → Outperform
    Wedbush
    1/6/2023$8.00 → $5.00Buy → Neutral
    BofA Securities
    6/13/2022$5.00Neutral
    Wedbush
    See more ratings

    Sangamo Therapeutics Inc. SEC Filings

    See more
    • Sangamo Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)

      5/6/25 4:03:49 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Sangamo Therapeutics Inc.

      10-K - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)

      3/17/25 4:05:16 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)

      3/17/25 4:01:39 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)

      2/6/25 8:13:57 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Sangamo Therapeutics Inc.

      SCHEDULE 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

      1/7/25 6:47:23 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement

      8-K - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)

      12/30/24 4:23:28 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)

      12/9/24 9:27:28 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Sangamo Therapeutics Inc.

      EFFECT - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)

      11/20/24 12:15:14 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Sangamo Therapeutics Inc.

      S-8 - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)

      11/12/24 5:25:20 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-3 filed by Sangamo Therapeutics Inc.

      S-3 - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)

      11/12/24 5:24:04 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Sangamo Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer

      Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced the appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer. She will serve on the Executive Leadership team and report to Nathalie Dubois-Stringfellow, Sangamo's Chief Development Officer. Dr Rojkjaer succeeds Bettina Cockroft, M.D., M.B.A, who is leaving the company to pursue other opportunities. We thank her for her contributions. "We are thrilled to welcome Dr. Rojkjaer, an experienced physician, drug developer, and regulatory expert, to the Sangamo team," said Nathalie Dubois-Stringfellow, Chief Development Officer at Sangamo. "Her deep industry experience across all stages of clinical developm

      5/16/23 8:00:00 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Organogenesis Appoints Prathyusha Duraibabu to Board of Directors

      CANTON, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Prathyusha Duraibabu to the Company's Board of Directors, effective November 19, 2021. Ms. Duraibabu will serve as an independent director of the Company and member of the Audit Committee of the Board. "Prathyusha is a proven leader who brings significant expertise from a more than 24-year career in the technology and healthcare sectors, and has held senior leadership positio

      11/22/21 7:00:00 AM ET
      $ORGO
      $PACB
      $SGMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, to Chief Financial Officer

      Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today the appointment of Prathyusha Duraibabu, CPA, MBA as Senior Vice President and Chief Financial Officer, effective June 1, 2021. Ms. Duraibabu will lead all financial activities and report to the Chief Executive Officer. "Prathyusha has served as our Principal Accounting Officer for nearly two years and has contributed significantly to Sangamo with her wealth of experience and proven track record in optimizing financial strategy and operations, driving organizational change, and building diverse teams," said Sandy Macrae, Chief Executive Officer of Sangamo. "I look forward to Prathyusha's leadership and sa

      5/24/21 4:15:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Appoints Rob Schott, MD, MPH, FACC, as Head of Development; Elevates Jason Fontenot, PhD to Chief Scientific Officer

      BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Rob Schott, MD, MPH, FACC, as Senior Vice President and Head of Development. Dr. Schott will lead clinical strategy across all phases of development and regulatory approval and will report to Sandy Macrae, Sangamo’s Chief Executive Officer. Sangamo also announced today that, effective January 1, 2021, Jason Fontenot, PhD, has been promoted to Chief Scientific Officer. Dr. Fontenot has served as Sangamo’s Head of Cell Therapy since March 2019 and as the acting Interim Head of Research since June 2020. “I am delighted to welcome Rob to Sangamo

      2/1/21 4:05:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Announces Departure of Chief Financial Officer Sung Lee

      BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Chief Financial Officer Sung Lee is leaving the Company to pursue a new opportunity overseas. Mr. Lee’s last day of employment will be February 1, 2021. “Sung has contributed significantly to Sangamo’s evolution, helping us build a strong cash position to advance proprietary medicines for patients in need as we begin a year with several potential catalysts,” said Sandy Macrae, Chief Executive Officer of Sangamo. “I have deep appreciation for the integrity and leadership Sung brought to Sangamo. The management team and board of directors at Sangamo join me

      1/6/21 4:10:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Sangamo Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sangamo Therapeutics Inc.

      SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

      11/12/24 4:53:35 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sangamo Therapeutics Inc.

      SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

      11/4/24 1:54:32 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sangamo Therapeutics Inc.

      SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

      8/16/24 6:40:25 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Sangamo Therapeutics Inc. (Amendment)

      SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

      4/5/24 3:59:23 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Sangamo Therapeutics Inc. (Amendment)

      SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

      2/12/24 7:11:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Sangamo Therapeutics Inc. (Amendment)

      SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

      2/9/24 12:17:13 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Sangamo Therapeutics Inc. (Amendment)

      SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

      1/22/24 12:18:22 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Sangamo Therapeutics Inc. (Amendment)

      SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

      10/10/23 3:09:57 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Sangamo Therapeutics Inc. (Amendment)

      SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

      2/9/23 4:21:47 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Sangamo Therapeutics Inc. (Amendment)

      SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

      2/7/23 1:49:22 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Sangamo Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more

    Sangamo Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

      Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the company has scheduled the release of its first quarter 2025 financial results after the markets close on Monday, May 12, 2025. The company will hold a conference call at 4:30 p.m. Eastern on Monday, May 12, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the numbe

      5/6/25 4:35:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

      All dosed patients have passed one-year milestone required by U.S. Food and Drug Administration (FDA) for Accelerated Approval regulatory pathway for ST-920. According to preliminary analysis, mean estimated glomerular filtration rate (eGFR) slope at 52-weeks continued to remain positive. Productive Type B Chemistry, Manufacturing and Controls (CMC) meeting with FDA provided clear CMC pathway to planned Biologics License Application (BLA) submission. Pivotal data readout expected by end of second quarter of 2025. Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced important derisking events in the pathway to a planned BLA submission for isaralgagen

      5/6/25 8:30:00 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

      One abstract accepted as platform presentation in prestigious Presidential Symposium, demonstrating potent combination of epigenetic regulation and capsid delivery technology in treating prion disease in animal models Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted nine Sangamo abstracts for presentation at the 28th ASGCT Annual Meeting being held May 13-17, 2025, in-person in New Orleans, LA and in a virtual format. Presentations will highlight the progression of Sangamo's neurology pipeline, including advances in zinc finger epigenetic regulation, the latest innovations in capsid

      4/28/25 4:31:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

      Agreement grants Lilly rights to employ Sangamo's novel proprietary capsid, STAC-BBB, for up to five potential disease targets Sangamo to receive an $18 million upfront license fee and is eligible to earn up to $1.4 billion in additional licensed target fees and milestone payments across all five potential disease targets, as well as tiered royalties on potential net sales Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced it has entered into a license agreement with Eli Lilly and Company ("Lilly"), allowing Lilly to leverage Sangamo's novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, which has demonstrated potent blood-bra

      4/3/25 4:01:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

      Continued to advance our prioritized neurology genomic medicine pipeline towards the clinic. Announced two neurology license agreements with blue-chip pharma companies, including a global epigenetic regulation and capsid delivery license agreement with Genentech in August 2024 to develop novel genomic medicines for neurodegenerative diseases and a capsid license agreement with Astellas in December 2024 to deliver genomic medicines for up to five neurological disease targets. Raised over $100 million in funding in 2024 through non-dilutive license fees and milestone payments, as well as equity financing. Investigational new drug (IND) application cleared by U.S. Food and Drug Administrati

      3/17/25 4:01:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference

      Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter and full year 2024 financial results after the markets close on Monday, March 17, 2025. The company also plans to participate in an upcoming investor conference. Fourth Quarter and Full Year 2024 Earnings Results The company will hold its fourth quarter and full year 2024 results conference call at 4:30 p.m. Eastern on Monday, March 17, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this

      3/6/25 4:05:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

      Sustained benefit demonstrated with elevated expression of alpha-galactosidase A (α-Gal A) activity maintained for nearly four years for the longest treated patient as of the data cutoff date Positive mean estimated glomerular filtration rate (eGFR) slope observed in the 23 patients who had reached at least one-year follow-up, indicating notable improvements in renal function All 18 patients who began study on enzyme replacement therapy (ERT) have been withdrawn from, and remain off, ERT Data to support Accelerated Approval pathway expected in first half of 2025, with potential Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) anticipated in

      2/6/25 8:05:00 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer's Decision to Cease Development of Giroctocogene Fitelparvovec

      - Based on positive results from Phase 3 AFFINE trial, which met primary and secondary endpoints, Sangamo plans to explore all options to commercialize the asset, including seeking a potential new collaboration partner Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced it will regain development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for the treatment of adults with moderately severe to severe hemophilia A that it has co-developed with, and licensed to Pfizer Inc., following a decision by Pfizer to terminate the global collaboration and license agreement between the parties. Sangamo

      12/30/24 4:15:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

       - Agreement grants Astellas rights to employ Sangamo's novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets - - Sangamo to receive a $20 million upfront license fee and is eligible to earn up to $1.3 billion in additional licensed target fees and milestone payments across all five potential disease targets, as well as tiered royalties on potential net sales - TOKYO and RICHMOND, Calif., Dec. 19, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced they have entered into a license agreement allowing Astellas to leverage

      12/19/24 2:30:00 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

      - Agreement grants Astellas rights to employ Sangamo's novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets - Sangamo to receive a $20 million upfront license fee and is eligible to earn up to $1.3 billion in additional licensed target fees and milestone payments across all five potential disease targets, as well as tiered royalties on potential net sales Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), today announced they have entered into a license agreement allowing Astellas to leverage Sangamo's novel proprietary neurotropic adeno-associated v

      12/19/24 2:30:00 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

      Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the company has scheduled the release of its first quarter 2025 financial results after the markets close on Monday, May 12, 2025. The company will hold a conference call at 4:30 p.m. Eastern on Monday, May 12, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the numbe

      5/6/25 4:35:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

      Continued to advance our prioritized neurology genomic medicine pipeline towards the clinic. Announced two neurology license agreements with blue-chip pharma companies, including a global epigenetic regulation and capsid delivery license agreement with Genentech in August 2024 to develop novel genomic medicines for neurodegenerative diseases and a capsid license agreement with Astellas in December 2024 to deliver genomic medicines for up to five neurological disease targets. Raised over $100 million in funding in 2024 through non-dilutive license fees and milestone payments, as well as equity financing. Investigational new drug (IND) application cleared by U.S. Food and Drug Administrati

      3/17/25 4:01:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference

      Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter and full year 2024 financial results after the markets close on Monday, March 17, 2025. The company also plans to participate in an upcoming investor conference. Fourth Quarter and Full Year 2024 Earnings Results The company will hold its fourth quarter and full year 2024 results conference call at 4:30 p.m. Eastern on Monday, March 17, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this

      3/6/25 4:05:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results

      Announced clear regulatory pathway to Accelerated Approval from U.S. Food and Drug Administration (FDA) for isaralgagene civaparvovec in Fabry disease, using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years. Pfizer plans to present detailed data from Phase 3 AFFINE trial evaluating giroctocogene fitelparvovec, an investigational Hemophilia A gene therapy that Sangamo has co-developed with and licensed to Pfizer, via a platform presentation at the 66th American Society for Hematology (ASH) Annual Meeting and Exposition. Received $50 million in upfront licens

      11/12/24 4:01:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast

      Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that the company has scheduled the release of its third quarter 2024 financial results after the market close on Tuesday, November 12, 2024. The company will hold a conference call at 4:30 p.m. Eastern on Tuesday, November 12, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call wit

      11/4/24 4:15:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results

      Announced global epigenetic regulation and capsid delivery license agreement with Genentech to develop novel genomic medicines for neurodegenerative diseases. Expect to receive $50 million in near-term upfront license fees and milestone payments and eligible to earn up to $1.9 billion in milestone payments, plus tiered royalties on net sales. Reported Pfizer's announcement of positive topline results from Phase 3 AFFINE trial evaluating giroctocogene fitelparvovec, an investigational Hemophilia A gene therapy that Sangamo is co-developing with and licensing to Pfizer. Continue to amass encouraging safety and efficacy data from the Phase 1/2 STAAR study of isaralgagene civaparvovec for F

      8/6/24 4:01:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast

      Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that the company has scheduled the release of its second quarter 2024 financial results after the market close on Tuesday, August 6, 2024. The company will hold a conference call at 4:30 p.m. Eastern on Tuesday, August 6, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with t

      7/30/24 4:15:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast

      Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2024 financial results after the market closes on Thursday, May 9, 2024. The company will hold a conference call at 4:30 p.m. Eastern on Thursday, May 9, which will be open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the numbe

      5/2/24 4:15:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

      Data from novel proprietary neurotropic adeno-associated virus (AAV) delivery capsid, STAC-BBB, demonstrated industry-leading blood-brain barrier (BBB) penetration in non-human primates (NHPs) following intravenous administration, with capsid-enabled delivery of zinc finger payloads targeting prion disease and tauopathies resulting in potent and widespread repression of target genes. Chronic neuropathic pain and prion disease preclinical programs advance, with investigational new drug (IND) and clinical trial authorization (CTA) submissions expected in the fourth quarters of 2024 and 2025, respectively. Announced U.S. Food and Drug Administration (FDA) alignment on an abbreviated pat

      3/13/24 8:05:00 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs

      Novel AAV capsid engineered by Sangamo showed robust penetration of blood-brain barrier (BBB) and widespread transgene expression throughout brain in non-human primates (NHPs) following intravenous administration. Demonstrated industry-leading brain tropism and enrichment in NHPs, resulting in 700-fold higher transgene expression than benchmark capsid AAV9. Capsid-enabled delivery of zinc finger payloads targeting prion disease and tauopathies resulted in robust and widespread repression of target genes. STAC-BBB capsid could potentially unlock multiple neurology epigenetic regulation programs paused by Sangamo pending identification of suitable capsid and could be advanced either

      3/13/24 8:01:00 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Sangamo Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sangamo Therapeutics upgraded by Truist with a new price target

      Truist upgraded Sangamo Therapeutics from Hold to Buy and set a new price target of $7.00

      12/13/24 8:18:20 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright reiterated coverage on Sangamo Therapeutics with a new price target

      H.C. Wainwright reiterated coverage of Sangamo Therapeutics with a rating of Buy and set a new price target of $10.00

      12/10/24 11:58:57 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Sangamo Therapeutics from Outperform to Sector Perform and set a new price target of $2.00 from $6.00 previously

      11/3/23 7:45:03 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics downgraded by BofA Securities with a new price target

      BofA Securities downgraded Sangamo Therapeutics from Neutral to Underperform and set a new price target of $1.50 from $5.00 previously

      4/28/23 7:25:59 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics upgraded by Wedbush with a new price target

      Wedbush upgraded Sangamo Therapeutics from Neutral to Outperform and set a new price target of $16.00

      2/27/23 7:43:59 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics downgraded by BofA Securities with a new price target

      BofA Securities downgraded Sangamo Therapeutics from Buy to Neutral and set a new price target of $5.00 from $8.00 previously

      1/6/23 12:46:54 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wedbush resumed coverage on Sangamo Therapeutics with a new price target

      Wedbush resumed coverage of Sangamo Therapeutics with a rating of Neutral and set a new price target of $5.00

      6/13/22 7:52:02 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • RBC Capital initiated coverage on Sangamo Therapeutics with a new price target

      RBC Capital initiated coverage of Sangamo Therapeutics with a rating of Outperform and set a new price target of $22.00

      5/4/21 6:33:12 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • RBC Capital initiated coverage on Sangamo Therapeutics with a new price target

      RBC Capital initiated coverage of Sangamo Therapeutics with a rating of Sector Perform and set a new price target of $22.00

      5/4/21 6:33:12 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wells Fargo & Company reiterated coverage on Sangamo Therapeutics with a new price target

      Wells Fargo & Company reiterated coverage of Sangamo Therapeutics with a rating of Overweight and set a new price target of $29.00 from $36.00 previously

      3/3/21 8:17:52 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Sangamo Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, GEN. COUNSEL & SECRETARY Willoughby Scott B. covered exercise/tax liability with 31,866 shares, decreasing direct ownership by 4% to 782,976 units (SEC Form 4)

      4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

      4/24/25 4:10:48 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP, CHIEF FINANCIAL OFFICER Duraibabu Prathyusha covered exercise/tax liability with 31,866 shares, decreasing direct ownership by 4% to 779,937 units (SEC Form 4)

      4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

      4/24/25 4:09:40 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PRESIDENT, CEO AND DIRECTOR Macrae Sandy covered exercise/tax liability with 126,950 shares, decreasing direct ownership by 5% to 2,325,898 units (SEC Form 4)

      4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

      4/24/25 4:08:28 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP-CHIEF DEVELOPMENT OFFICER Dubois-Stringfellow Nathalie covered exercise/tax liability with 31,866 shares, decreasing direct ownership by 4% to 801,539 units (SEC Form 4)

      4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

      4/24/25 4:07:02 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Head of Research & Technology Davis Gregory D covered exercise/tax liability with 6,708 shares, decreasing direct ownership by 3% to 209,376 units (SEC Form 4)

      4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

      4/24/25 4:05:13 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Head of Research & Technology Davis Gregory D covered exercise/tax liability with 1,212 shares and was granted 49,726 shares, increasing direct ownership by 29% to 216,084 units (SEC Form 4)

      4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

      2/26/25 5:33:13 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP-CHIEF DEVELOPMENT OFFICER Dubois-Stringfellow Nathalie covered exercise/tax liability with 3,305 shares and was granted 120,000 shares, increasing direct ownership by 16% to 833,405 units (SEC Form 4)

      4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

      2/26/25 5:32:37 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP, GEN. COUNSEL & SECRETARY Willoughby Scott B. covered exercise/tax liability with 2,809 shares and was granted 120,000 shares, increasing direct ownership by 17% to 814,842 units (SEC Form 4)

      4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

      2/26/25 5:32:04 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP, CHIEF FINANCIAL OFFICER Duraibabu Prathyusha covered exercise/tax liability with 3,167 shares and was granted 120,000 shares, increasing direct ownership by 17% to 811,803 units (SEC Form 4)

      4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

      2/26/25 5:31:20 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PRESIDENT, CEO AND DIRECTOR Macrae Sandy covered exercise/tax liability with 18,151 shares and was granted 375,000 shares, increasing direct ownership by 17% to 2,452,848 units (SEC Form 4)

      4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

      2/26/25 5:30:33 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care